Fig. 5: AF4H1K1 showed prophylactic and therapeutic activities against H3 and H7 IAVs.

a–d Prophylactic and therapeutic efficacies of AF4H1K1 against H3-rAC/68. In the H3-infected experiments, BALB/c mice were intravenously administrated with 15 mg/kg of AF4H1K1 via tail veil 1 day before, or 4, 24, and 48 hours (hrs) after being challenged with 100 MID₅₀ (15 mice per group). Anti-Ebola MAb 13C6-treated mice were used as a control. Lung tissues were collected, homogenized for the virus titration at 3 dpi (a, c) and 5 dpi (b, d), respectively. AF4H1K1 could reduce the virus replication in the lung of virus-infected mice in both preexposure prophylactic evaluation (a, b) and therapeutic assessment tests (c, d) according to the unpaired t-tests (n = 5) using GraphPad Prism 5 software. *P < 0.05, **P < 0.01, ***P < 0.001. They are one representative experiment out of three. e–h Evaluation of prophylactic and therapeutic efficacies of AF4H1K1 against H7N9 HPAIV. In the H7N9 IAV-challenged experiments, BALB/c mice were intravenously administrated with 15 mg/kg of AF4H1K1 via tail veil at 1 day  before or after virus challenge with 10⁵ 50% of lethal dose (LD₅₀) (equally to 10⁷ 50% egg infective dose (EID₅₀)). AF4H1K1 and AF4H1/FI6v3L were fully protective against the lethality when being administrated at 24 h before (e) and after (f) virus challenge, but could not prevent the body weight from dropping in both prophylactic (g) and therapeutic (h) experiments. n = 5. They are one representative experiment out of two, which have been done in Biosafety level 3 laboratory. Survival analysis was carried out by Kaplan–Meier method using GraphPad Prism 5 software